Diagnosis & Disease Information

Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma

February 23, 2018

Researchers report on finding of a double-blind phase 3 study on the efficacy of adjuvant vemurafenib in patients with resected stage IIC to IIIB melanoma.

Web Exclusives

Complete recovery from hairy cell leukemia after vemurafenib treatment

Kathy Boltz, PhD

February 11, 2014

Vemurafenib, a BRAF inhibitor that has been approved as a treatment for advanced melanomas, has also proved successful in treating hairy cell leukemia.

Web Exclusives

New BRAF biomarker may guide melanoma treatment

Kathy Boltz, PhD

November 8, 2013

A functional biomarker that can predict whether BRAF-mutant melanomas respond to drugs targeting BRAF could help guide the treatment of patients with these cancers.